Alebund Pharmaceuticals (Jiangsu) Limited issued and allotted 8.51 million H shares on 29 July 2026 following the full exercise of the over-allotment option disclosed on 24 July 2026. The shares were priced at HKD 22.60 each, implying gross proceeds of approximately HKD 192.40 million.

The transaction lifted the company’s issued H shares to 235.64 million from 227.12 million at the end of June. Unlisted shares remained unchanged at 112.73 million. Consequently, total issued share capital expanded to 348.37 million shares, compared with 339.85 million in the previous month.

The company confirmed that it continues to meet the Hong Kong Exchange’s public-float requirement, with no treasury shares outstanding. During the reporting period, Alebund Pharmaceuticals reported no movements related to share options, warrants, convertibles or other equity instruments.